BABA
Alibaba Group Holding Limited
BABA offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
SCI
Service Corporation International
SCI has a slight edge over BABA overall, supported by stronger fundamentals and lower modeled downside.
BABA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Healthy |
BABA's balance sheet is currently healthy, and its revenue is stable, but its profitability and cash flow are under pressure.
SCI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Weak |
SCI's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is weak.
BABA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 16x | $69.66 | -26% |
| Fair | 20x | $86.59 | -8.2% |
| Current | 21x | $94.36 | — |
| Expensive | 26x | $115 | +22% |
Historical ranges are pointers, not guarantees.
BABA's PE is 21x, but its earnings don't support one, so it isn't a reliable read right now.
SCI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $60.18 | -20% |
| Forward | 18x | $74.97 | — |
| Current | 19x | $74.97 | — |
| Fair | 20x | $80.86 | +7.9% |
| Expensive | 22x | $88.36 | +18% |
Historical ranges are pointers, not guarantees.
SCI has the edge over BABA in the historical PE scenario, which offers more potential upside but is not a forecast.
BABA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
BABA has the edge over SCI on the outlook, with more favorable revenue and profitability expectations.
SCI Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Stable | |
| Stable | |
| Limited | |
| High |
Analysts expect SCI's earnings to grow, with its revenue and profitability holding steady.
BABA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $4.42 | -52% |
| Q1 2026 | $6.57 | -18% |
| Q4 2025 | $5.79 | -22% |
| Q3 2025 | $7.85 | +49% |
| Q2 2025 | $9.27 | +116% |
| Q1 2025 | $8.06 | +71% |
| Q4 2024 | $7.47 | +24% |
| Q3 2024 | $5.26 | -35% |
BABA's earnings per share have fallen from their peak: $4.42 over the past year, against $9.27 in mid-2025. Its recent earnings include one-off gains.
SCI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.22 | +4.8% |
| Q3 2026 | $4.03 | +9.2% |
| Q2 2026 | $3.83 | +4.4% |
| Q1 2026 | $3.79 | +4.7% |
| Q4 2025 | $3.80 | +7.6% |
| Q3 2025 | $3.69 | +7% |
| Q2 2025 | $3.67 | +6.7% |
| Q1 2025 | $3.62 | +3.7% |
| Q4 2024 | $3.53 | 0% |
SCI has the edge over BABA on earnings, with more consistent year-over-year improvement.
BABA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $40.2B | +8.3% |
| Q1 2026 | $36.5B | +2.9% |
| Q4 2025 | $42.7B | +1.7% |
| Q3 2025 | $37.2B | +4.8% |
| Q2 2025 | $37.2B | +1.8% |
| Q1 2025 | $35.5B | +6.6% |
| Q4 2024 | $42B | +7.6% |
| Q3 2024 | $35.5B | +5.2% |
BABA has the edge over SCI on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 7.2% | -6.9 points |
| Q1 2026 | -0.3% | -12 points |
| Q4 2025 | 7.1% | -7.6 points |
| Q3 2025 | 2.2% | -13 points |
| Q2 2025 | 14% | -0.7 points |
| Q1 2025 | 12% | +5.4 points |
| Q4 2024 | 15% | +6.1 points |
| Q3 2024 | 15% | 0 points |
BABA's operating margin was 7.2% last quarter, down 6.9 points from the same quarter a year ago.
SCI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +4.6% |
| Q2 2026 | $1.1B | +3.6% |
| Q1 2026 | $1.1B | +2.1% |
| Q4 2025 | $1.1B | +1.7% |
| Q3 2025 | $1.1B | +4.4% |
| Q2 2025 | $1.1B | +3% |
| Q1 2025 | $1.1B | +2.8% |
| Q4 2024 | $1.1B | +3.5% |
SCI's revenue has grown year over year for 14 quarters in a row: $1.1B last quarter, up 4.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 23% | +1.4 points |
| Q2 2026 | 21% | -0.1 points |
| Q1 2026 | 22% | -1.2 points |
| Q4 2025 | 25% | +0.8 points |
| Q3 2025 | 21% | +0.4 points |
| Q2 2025 | 21% | -0.3 points |
| Q1 2025 | 23% | +1.2 points |
| Q4 2024 | 24% | +1.1 points |
SCI has the edge over BABA on profitability, with a higher operating margin.
BABA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$6.7B | -$4.1B |
| Q1 2026 | -$2.7B | +$1.5B |
| Q4 2025 | $1B | -90% |
| Q3 2025 | -$3.2B | -254% |
| Q2 2025 | -$2.7B | -182% |
| Q1 2025 | -$4.2B | -12231% |
| Q4 2024 | $10.4B | -4.8% |
| Q3 2024 | $2.1B | -62% |
BABA's free cash flow has turned negative after years in the green: −$11.6B over the past year.
SCI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $197.4M | +31% |
| Q2 2026 | $142.9M | +71% |
| Q1 2026 | $253.9M | +9% |
| Q4 2025 | $87.2M | -43% |
| Q3 2025 | $150.7M | -7.5% |
| Q2 2025 | $83.4M | -17% |
| Q1 2025 | $233M | +66% |
| Q4 2024 | $151.8M | -17% |
SCI has the edge over BABA on cash generation, producing positive trailing cash flow while its opponent burns cash.
BABA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +11.1M shares |
| 1 year | +0.9% | +21.4M shares |
| 3 years | -6.2% | -161M shares |
| 5 years | -12% | -339M shares |
| Available history | -8.4% | -221M shares |
BABA has 2.4B diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $269.8M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
BABA spent $270M buying back its own shares over the past year, after none the year before.
SCI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -1.1M shares |
| 1 year | -3% | -4.2M shares |
| 3 years | -9.9% | -15.1M shares |
| 5 years | -19% | -32.8M shares |
| Available history | -26% | -48.3M shares |
SCI has the edge over BABA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $52.6M |
| Q2 2026 | $123.2M |
| Q1 2026 | $143.2M |
| Q4 2025 | $58.9M |
| Q3 2025 | $78.1M |
| Q2 2025 | $193.6M |
| Q1 2025 | $130.5M |
| Q4 2024 | $56.2M |
SCI spent $378M buying back its own shares over the past year, down 18% from the year before.
BABA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.8x | Very low |
| Q2 2025 | 0.2x | Very low |
| Q1 2025 | 0.3x | Very low |
| Q4 2024 | 0.1x | Very low |
| Q3 2024 | -0.2x | Net Cash |
BABA has the edge over SCI on leverage, with a lower net debt burden relative to earnings.
SCI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 4.0x | High |
| Q2 2026 | 4.1x | High |
| Q1 2026 | 4.1x | High |
| Q4 2025 | 4.0x | High |
| Q3 2025 | 4.0x | Elevated |
| Q2 2025 | 4.0x | High |
| Q1 2025 | 3.9x | Elevated |
| Q4 2024 | 4.0x | Elevated |
SCI's net debt is about 4.0 years of its operating earnings (EBITDA), about the same as a year ago.
BABA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.0 | Neutral |
| Stochastic | 12.7 | Oversold |
BABA's weekly RSI is 38 (neutral) and its Stochastic is 13 (oversold).
SCI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.2 | Neutral |
| Stochastic | 31.6 | Neutral |
SCI's weekly RSI is 43 (neutral) and its Stochastic is 32 (neutral).
BABA PE vs Consumer Cyclical Sector
| Metric | BABA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 18x | 19% above |
| PE % | 60 | 47 | 13 pts above |
BABA is trading at 21x earnings, a 19% premium to the Consumer Cyclical sector's median of 18x, though its earnings don't support one.
SCI PE vs Consumer Cyclical Sector
| Metric | SCI | Sector median | Relative |
|---|---|---|---|
| PE | 19x | 18x | 3.2% above |
| PE % | 34 | 47 | 13 pts below |
SCI has the edge over BABA on valuation relative to its sector.
BABA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $104.7 | 9.9% below |
| 20 week MA | $111.1 | 15% below |
| 50 week MA | $128.0 | 26% below |
| 100 week MA | $127.7 | 26% below |
| 200 week MA | $106.4 | 11% below |
BABA is in a downtrend: it's below all five of its weekly moving averages, and 11% below its 200-week average.
SCI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $77.7 | 3.5% below |
| 20 week MA | $80.2 | 6.5% below |
| 50 week MA | $79.7 | 5.9% below |
| 100 week MA | $79.5 | 5.7% below |
| 200 week MA | $74.6 | 0.5% above |
SCI has the edge over BABA on trend strength, trading above more of its moving averages.
BABA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $215.5 | $222.0 | +3% |
| 2021 | $222.0 | $118.7 | -47% |
| 2022 | $118.7 | $85.7 | -28% |
| 2023 | $85.7 | $77.5 | -9.5% |
| 2024 | $77.5 | $85.1 | +9.7% |
| 2025 | $85.1 | $152.2 | +79% |
| 2026 YTD | $152.2 | $94.4 | -38% |
BABA has finished lower in three of the last six years. It's down 38% so far in 2026.
SCI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $46.1 | $48.7 | +5.6% |
| 2021 | $48.7 | $69.7 | +43% |
| 2022 | $69.7 | $70.2 | +0.8% |
| 2023 | $70.2 | $68.5 | -2.5% |
| 2024 | $68.5 | $80.8 | +18% |
| 2025 | $80.8 | $78.0 | -3.5% |
| 2026 YTD | $78.0 | $75.0 | -3.8% |
SCI has the edge over BABA on returns for 2026, with the stronger performance.